Gayle Sheppard is Appointed to the NovaSignal Advisory Board

September 11, 2020

Gayle Sheppard has been appointed to the NovaSignal advisory board.

Gayle Sheppard is a global technology entrepreneur and leader with a proven track record of scaling small- and medium-sized companies to a market-leading position. As Chairman and CEO of Saffron Technology, Inc., a predictive reasoning solution for enterprise decision making, Sheppard successfully grew the business to $20M in revenue and an acquisition in 2015 by Intel, where she continued to lead the business through 2018. Currently, Sheppard serves as Corporate Vice President of Azure Data at Microsoft, where she is responsible for the vision, strategy, and long-range P&L for growing Microsoft’s Cloud Services with customers who are implementing multiyear digital innovation and modernization strategies.

Earlier in her career, Sheppard held the role of Vice President and Managing Director at PeopleSoft and served as CEO and President of MarketMile (now part of Rearden Commerce), where she led the development and launch of a software-as-a-service e-procurement business for American Express.

“Gayle’s global experience in successfully building companies – specifically those fueled by artificial intelligence – will be invaluable as we scale to meet the growing demand and extend the reach and impact of our solutions worldwide. I personally look forward to benefiting from her relevant expertise and advice,” said Diane Bryant, Chairman and CEO of NovaSignal.

“I am honored and excited to join such a strong team of technology leaders with the vision of ending brain disease through cerebral blood flow analysis,” said Sheppard. “With Saffron I built a team and business that solved real world problems and delivered shareholder value. To work with NovaSignal in achieving industry leadership is a great honor.”

Sheppard is a graduate of the University of South Florida, where she received a B.S. in Business Administration with a focus in operations research and management science.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.